204 related articles for article (PubMed ID: 10526669)
21. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
[TBL] [Abstract][Full Text] [Related]
22. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Eeles RA; Powles TJ
J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
[TBL] [Abstract][Full Text] [Related]
23. A survey of preventive measures among BRCA1 mutation carriers from Poland.
Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
[TBL] [Abstract][Full Text] [Related]
24. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
Steinmann D; Bremer M; Rades D; Skawran B; Siebrands C; Karstens JH; Dörk T
Br J Cancer; 2001 Sep; 85(6):850-8. PubMed ID: 11556836
[TBL] [Abstract][Full Text] [Related]
25. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
Vaziri SA; Krumroy LM; Rostai M; Casey G
Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
[TBL] [Abstract][Full Text] [Related]
26. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
[TBL] [Abstract][Full Text] [Related]
27. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
Shih HA; Nathanson KL; Seal S; Collins N; Stratton MR; Rebbeck TR; Weber BL
Clin Cancer Res; 2000 Nov; 6(11):4259-64. PubMed ID: 11106241
[TBL] [Abstract][Full Text] [Related]
28. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
29. A genetic epidemiological study of carcinoma of the fallopian tube.
Aziz S; Kuperstein G; Rosen B; Cole D; Nedelcu R; McLaughlin J; Narod SA
Gynecol Oncol; 2001 Mar; 80(3):341-5. PubMed ID: 11263928
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer.
Gershoni-Baruch R; Dagan E; Fried G; Kepten I; Robinson E
Eur J Hum Genet; 1999; 7(7):833-6. PubMed ID: 10573018
[TBL] [Abstract][Full Text] [Related]
31. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.
Gronwald J; Byrski T; Huzarski T; Cybulski C; Sun P; Tulman A; Narod SA; Lubinski J
Breast Cancer Res Treat; 2006 Jan; 95(2):105-9. PubMed ID: 16261399
[TBL] [Abstract][Full Text] [Related]
32. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
33. Psychological impact of receiving a BRCA1/BRCA2 test result.
Lodder L; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Duivenvoorden HJ; Tibben A; Wagner A; van der Meer CA; van den Ouweland AM; Niermeijer MF
Am J Med Genet; 2001 Jan; 98(1):15-24. PubMed ID: 11426450
[TBL] [Abstract][Full Text] [Related]
34. Risk of breast cancer in carriers of BRCA gene mutations.
Birkmeyer JD; Welch HG
N Engl J Med; 1997 Sep; 337(11):787-8; author reply 789. PubMed ID: 9289638
[No Abstract] [Full Text] [Related]
35. [Genetic test and prophylactic treatment in breast cancer families].
Miyoshi Y; Noguchi S
Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
[TBL] [Abstract][Full Text] [Related]
36. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
37. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT
Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846
[TBL] [Abstract][Full Text] [Related]
39. Risk of breast cancer in carriers of BRCA gene mutations.
Orlando R
N Engl J Med; 1997 Sep; 337(11):787; author reply 789. PubMed ID: 9289637
[No Abstract] [Full Text] [Related]
40. [INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and/or ovarian cancer].
Eisinger F; Alby N; Bremond A; Dauplat J; Espié M; Janiaud P; Kuttenn F; Lebrun JP; Lefranc JP; Pierret J; Sobol H; Stoppa-Lyonnet D; Thouvenin D; Tristant H; Feingold J
Ann Genet; 1999; 42(1):51-64. PubMed ID: 10214508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]